We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cytokine Target Identified for Treatment-Resistant Hemophilia A

By LabMedica International staff writers
Posted on 04 May 2021
Hemophilia A, also called factor VIII (8) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII (FVIII), a clotting protein. More...
Although it is passed down from parents to children, about 1/3 of cases found have no previous family history.

Currently, hemophilia is the most common inherited bleeding disorder, which affects 1 in 10,000 men across the globe. Since patients lack coagulation factor VIII (FVIII), therapies are typically aimed at infusions to replace the missing protein. Some patients, however, become treatment resistant due to the development of neutralizing antibodies, or FVIII inhibitors.

An international team of hematologists and their associates led by those at the Children’s Hospital of Philadelphia (Philadelphia, PA, USA) used plasma samples from 69 pediatric patients undergoing recombinant FVIII therapy, in addition to samples from mouse models, to determine whether cytokine B cell activating factor (BAFF) may help generate and sustain FVIII antibodies. Of the pediatric patients, 24 had FVIII inhibitors.

BAFF, proliferation-inducing ligand (APRIL), and B cell maturation antigen (BCMA) levels from the patient samples were measured by a multiplex ELISA Because of limitations on sample transport, BAFF levels from rituximab-exposed patients were measured by ELISA (R&D Systems, Minneapolis, MN, USA). The frequency of FVIII-specific immunoglobulin-secreting B cells was quantified by a B cell ELISPOT assay. Plates were analyzed using the ImmunoSpot system (Cellular Technology Limited, Shaker Heights, OH, USA).

The team reported that BAFF levels to be higher in patients with persistent FVIII inhibitors compared to those without inhibitors (1.30 versus 0.99 ng/mL, respectively). Moreover, BAFF levels decreased from baseline in hemophilia A inhibitor patients who underwent immune tolerance induction (ITI) and achieved FVIII tolerance from 1.43 ± 0.63 to 0.81 ± 0.32 ng/mL. In comparison, those who failed ITI had steady levels at 1.33 to 1.23 ng/mL. A similar pattern and trend in BAFF levels was also noted for 46 adults, although non-inhibitor patients saw a generally higher level of BAFF. Furthermore, a receiver-operating characteristic (ROC) analysis of the pooled pediatric and adult data showed that BAFF levels greater than 1.03 ng/mL had 68.3% sensitivity, 63.8% specificity, and likelihood ratio of 1.89 for the presence of FVIII inhibitors.

Valder R. Arruda, MD, PhD, a Hematologist and senior author of the study, said, “Our data suggest that BAFF may regulate the generation and maintenance of FVIII inhibitors, as well as anti-FVIII B cells. Given that an FDA-approved anti-BAFF antibody is currently used to suppress the immune response in autoimmune diseases, future studies should explore the use of this treatment in combination with rituximab to achieve better outcomes for hemophilia A patients resistant to FVIII protein replacement therapy.”

The authors concluded that their data suggest that BAFF may regulate the generation and maintenance of FVIII inhibitors and/or anti-FVIII B cells. Finally, antiCD20/anti-BAFF combination therapy may be clinically useful for ITI. The study was published on April 15, 2021 in The Journal of Clinical Investigation.

Related Links:
Children’s Hospital of Philadelphia
R&D Systems
Cellular Technology Limited



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.